Impact of PCSK9 and acid ceramidase on obese hypothyroidism female patients

dc.contributor.authorMohammed Rajab Abed AL-Joboury
dc.contributor.authorNagham Qasim Kadhim
dc.contributor.authorSaif M. Hasan
dc.date.accessioned2025-12-29T08:05:59Z
dc.date.issued2024-08-23
dc.description.abstractProprotein Convertase subtilisin Kexin type 9 (PCSK9) is a serine protease composed of 692 residues. Acid ceramidase is an enzyme that hydrolyzed ceramide to sphingosine and fatty acids
dc.formatapplication/pdf
dc.identifier.urihttps://peerianjournal.com/index.php/tpj/article/view/922
dc.identifier.urihttps://asianeducationindex.com/handle/123456789/14587
dc.language.isoeng
dc.publisherPeerian Journals Publishing
dc.relationhttps://peerianjournal.com/index.php/tpj/article/view/922/761
dc.rightshttps://creativecommons.org/licenses/by/4.0
dc.sourceThe Peerian Journal; Vol. 33 (2024): TPJ; 65-71
dc.source2788-0303
dc.subjectHypothyroidism
dc.subjectobesity
dc.subjectPCSK9 and acid ceramidase
dc.titleImpact of PCSK9 and acid ceramidase on obese hypothyroidism female patients
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Article

item.page.files

item.page.filesection.original.bundle

pagination.showing.labelpagination.showing.detail
loading.default
thumbnail.default.alt
item.page.filesection.name
al-joboury_2024_impact_of_pcsk9_and_acid_ceramidase_on_o.pdf
item.page.filesection.size
293.63 KB
item.page.filesection.format
Adobe Portable Document Format

item.page.collections